Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X about a paper by Shaji Kumar et al. published in NEJM:
“Just out in the New England Journal of Medicine!
Effective therapy of extra medullary relapsed myeloma with teclistamab plus talquetamab (Tec-Tal).
RedirecTT-1
80% response rate. 60% PFS at 12 months.”
Title: Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
Authors: Shaji Kumar, María-Victoria Mateos, Jing Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael P. Chu, Suzanne Trudel, Joshua Richter, Paula Rodríguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey V. Matous, Laura Rosiñol, Koichi Onodera, Emma Scott, Christoph Heuck, Jenny Zhang, Todd Henninger, Lisa O’Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiangxiu Zhou, Mikihiro Takamoto, Lixia Pei, Jiashen Lu, Nicholas Au, Maria Krevvata, Saad Z. Usmani, Yael C. Cohen
You can read the full article in NEJM.
More posts featuring Vincent Rajkumar on OncoDaily.